亚马逊总裁贝佐斯看上的人 是这样做抗衰老研究的

2018-09-05 凌武娟(编译) 健康界

衰老不仅是广大爱美女性要对抗的皱纹,更意味着糖尿病、心脏病、阿尔兹海默式症、癌症等一系列疾病的到来。过去十年中,包括谷歌在内的科技巨头们,都在致力投资抗衰老前沿研究。在众多进行衰老研究的公司中,Unity Biotechnology以其创新的研究得到了亚马逊创始人杰夫·贝佐斯(Jeff Bezos)和贝宝(PayPal)联合创始人Peter Thiel的投资,估值达到7亿美元。2017061906

衰老不仅是广大爱美女性要对抗的皱纹,更意味着糖尿病、心脏病、阿尔兹海默式症、癌症等一系列疾病的到来。过去十年中,包括谷歌在内的科技巨头们,都在致力投资抗衰老前沿研究。

在众多进行衰老研究的公司中,Unity Biotechnology以其创新的研究得到了亚马逊创始人杰夫·贝佐斯(Jeff Bezos)和贝宝(PayPal)联合创始人Peter Thiel的投资,估值达到7亿美元。


亚马逊总裁贝佐斯

新奇的抗衰思想:与衰老有关的疾病是关键

Unity Biotechnology于2009年由Nathaniel David和生物学领域的一众教授创立,Nathaniel David为公司总裁。其独特之处在于,它不只是简单地关注衰老本身,而是将重点放在研发抗衰老的方法和治疗衰老相关疾病的药物上。“我们是通过特定疾病的视角来看待衰老。”同样是分子和细胞生物学家的David说。

FDA发言人表示,“对衰老的研究,以及将衰老视为一种疾病的观点,是一个新的研究领域。”虽然Unity Biotechnology对抗衰老临床研究的设计完全符合FDA批准规则,但操作起来依然困难重重。因此,该公司从个别疾病的治疗设计入手。其CEO Keith Leonard说:“直接从那些已知可以治疗的衰老相关疾病下手。因为对于这些疾病,我们知道要进行什么样的临床试验,患者是谁,需要什么指标。”

新颖的治疗模式:从骨关节炎入手

骨关节炎是Unity Biotechnology入手的第一种疾病。数据显示,到2026年,美国骨关节炎药物市场将达到26亿美元。该公司的骨关节炎药物目前正处于试验阶段Ι,纳入了约40名受试患者。试验发现,这种药物可以破坏衰老细胞,有效地阻止或逆转膝盖骨关节炎。将来,同样的药物可能有效治疗身体其他部位的疼痛。

“最初能治疗骨关节炎的药物是布洛芬,后来出现类固醇,然后大多数人的‘治疗想法’却是接受衰老。”David说,“但我们认为有更好的治疗方法,可通过研究生物体本身来解释为什么这些疾病会发生。”

清除衰老细胞的动物实验结果可喜

从生物体中清除衰老细胞的动物试验已经出现可喜结果。Unity Biotechnology联合创始人Jan van Deursen,同时也是梅奥医学中心的分子生物学家,在2016年发表了一项破坏衰老细胞的开创性衰老研究。该研究表明,对于同一天出生并在相同条件下饲养的小鼠,被清除了衰老细胞的小鼠看起来更年轻,寿命延长了三分之一,同时肾功能还得到改善,抗压能力也更强。

尽管衰老细胞是Unity Biotechnology重点关注项,但“健康寿命(healthspan)”是Unity Biotechnology更关心的问题。Unity Biotechnology的想法是,对骨关节炎等疾病的有效治疗可以使人更健康、活得更长久。

假设Unity Biotechnology的第一阶段试验顺利进行,David表示将进行下一步试验,可能通过测量体征和症状,以确定该公司的药物对患者衰老细胞的影响。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1940499, encodeId=fff91940499de, content=<a href='/topic/show?id=41a12431862' target=_blank style='color:#2F92EE;'>#亚马逊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24318, encryptionId=41a12431862, topicName=亚马逊)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Aug 09 13:36:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342956, encodeId=bfa0342956a2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 05 22:54:07 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342953, encodeId=e5db342953d3, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:43:10 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342952, encodeId=459334295232, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:42:55 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342938, encodeId=4cd63429388e, content=加大研究力度, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 05 22:18:02 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2019-08-09 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1940499, encodeId=fff91940499de, content=<a href='/topic/show?id=41a12431862' target=_blank style='color:#2F92EE;'>#亚马逊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24318, encryptionId=41a12431862, topicName=亚马逊)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Aug 09 13:36:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342956, encodeId=bfa0342956a2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 05 22:54:07 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342953, encodeId=e5db342953d3, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:43:10 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342952, encodeId=459334295232, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:42:55 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342938, encodeId=4cd63429388e, content=加大研究力度, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 05 22:18:02 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 天地飞扬

    了解一下,谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1940499, encodeId=fff91940499de, content=<a href='/topic/show?id=41a12431862' target=_blank style='color:#2F92EE;'>#亚马逊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24318, encryptionId=41a12431862, topicName=亚马逊)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Aug 09 13:36:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342956, encodeId=bfa0342956a2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 05 22:54:07 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342953, encodeId=e5db342953d3, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:43:10 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342952, encodeId=459334295232, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:42:55 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342938, encodeId=4cd63429388e, content=加大研究力度, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 05 22:18:02 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 惠映实验室

    学习了,谢谢分享。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1940499, encodeId=fff91940499de, content=<a href='/topic/show?id=41a12431862' target=_blank style='color:#2F92EE;'>#亚马逊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24318, encryptionId=41a12431862, topicName=亚马逊)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Aug 09 13:36:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342956, encodeId=bfa0342956a2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 05 22:54:07 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342953, encodeId=e5db342953d3, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:43:10 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342952, encodeId=459334295232, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:42:55 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342938, encodeId=4cd63429388e, content=加大研究力度, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 05 22:18:02 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 惠映实验室

    学习了,谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1940499, encodeId=fff91940499de, content=<a href='/topic/show?id=41a12431862' target=_blank style='color:#2F92EE;'>#亚马逊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24318, encryptionId=41a12431862, topicName=亚马逊)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Aug 09 13:36:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342956, encodeId=bfa0342956a2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 05 22:54:07 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342953, encodeId=e5db342953d3, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:43:10 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342952, encodeId=459334295232, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 05 22:42:55 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342938, encodeId=4cd63429388e, content=加大研究力度, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 05 22:18:02 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 医者仁心5538

    加大研究力度

    0

相关资讯

Cell Metab:节食或许真能长寿!耗时2年,普通人研究终于坐实这一点

怎样才能长寿?随着抗衰老领域在过去四十多年里取得的显着进步,一些答案也逐渐浮出水面。有些科学家们相信,寿命的长短与代谢率有关——代谢较快的动物,往往活得都不是很久。这可能是由于代谢产物会对细胞造成损伤和负面影响。

AGING:研究人员发现新型抗衰老因子

由线粒体稳态丧失引发的突出表型是细胞衰老,其特征在于生长停止和衰老相关的分泌表型(SASP)。

世界上预期寿命**的三个国家:抗衰老的更佳食物是什么?

健康长寿——这是我们都很熟悉的箴言,但是帮助我们实现这个目标的最好的食物是什么呢?在这篇文章中,我们给你介绍一些最健康和最有营养的食物。

Sci Transl Med:回拨“生命发条”,促进“老龄健康”,老年人抗免疫衰老药物方案

人类梦寐以求的抗衰老,离梦想成真又近了一步。老年人抗免疫衰老药物方案临床大发现,竟然是归因于人体内这个类似“生命发条”分子:TORC1。老年人使用靶向抑制TORC1 疗法,不仅可减少感染发病率, 还能提升免疫力,改善流感疫苗接种反应和抗病毒免疫。靶向抑制TORC1 疗法延缓老年人衰老,具有重要临床意义,其临床益处包括:改善免疫功能和降低感染发生率。

EMBO J:新研究有望增强端粒酶抗衰老功能

人们都希望能永葆年轻,细胞中的端粒酶就具有让细胞“不老”的潜力。一项新研究揭示了增强端粒酶抗衰老功能的途径,有望用于治疗先天性角化不良等相关疾病。

Science:科学背书!从精液中发现的亚精胺,竟然有着抗衰老、抗癌、保护心血管和神经、改善肥胖和2型糖尿病等逆天神效

2018年1月,顶级期刊《科学》杂志为此发表了一篇重磅文章,综述了130多篇科研进展,详详细细地汇总了近些年来科学家们对于亚精胺神奇功能的研究,一句话概括下来就是,有关亚精胺的传说,竟然都有可能是真的。